3.4 Effect of PA extract on body weight
Another parameter to estimate the presence of diabetes is a body weight.
Due to an expansion of diabetes, reduction in body weight commonly
observed due to loss of muscle. The same results were observed in the DC
control group rats, the initial body weight of the DC group rats was
161±2.34 g, which was further estimated at end of the experimental study
and was found to be 148.5±4.29 g. The result suggests that the expansion
of diabetes decreases the body weight. The rats treated with thePA showed the increased in the body weight. The PA -treated
rats showed the initial body weight of 159.5±2.87, 162±3.72 and
160.5±4.12 g, at a dose of 50, 100 and 200 mg/kg, which was
significantly (p<0.001) enhanced at the end of the
experimental period. The final body weight was observed 183.5±3.84,
195.4±4.94 and 204±2.03 g, respectively (figure 2a). An almost similar
pattern of results was observed in the glibenclamide group rats, the
initial body weight was found to be 161±2.09 g and final body weight was
203±2.93.
The NC and NC treated group rats showed the almost similar pattern
22.03% in increased body weight at end of the study. DC group rats
showed the reduction in the body weight 8.19%, which suggests diabetes,
is indirectly estimated by a reduction in the body weight. PAtreatment showed the 13.02, 17.04 and 21.12% enhancement of body weight
(figure 2b). Glibenclamide showed the 21. 22% increase in body weight.
STZ induced DM rats showed the decrease BW throughout the experimental
study. Several researchers suggest that the reduction of body weight of
STZ induced DM rats is due to gluconeogenesis. During the DM condition,
there is the degradation of structural proteins and fats that lead to
enhanced muscle destruction (Ahmed et al., 2013, 2014b; Kumar et al.,
2014). STZ induced DM rats treated with PA showed the increased
body weight and suggesting the anti-diabetic effect by inhibition of
degradation of muscle proteins and fat.